Zobrazeno 1 - 10
of 49
pro vyhledávání: '"Ivor, Caro"'
Autor:
Luna Musib, Josina C. Reddy, Sravanthi Cheeti, Sandhya Girish, Jin Y. Jin, Pascal Chanu, Rene Bruno, Tong Lu, Ivor Caro, Xin Wang
Publikováno v:
Journal of Investigative Dermatology. 141:930-933
Summary Long-term use of vismodegib is associated with treatment-emergent adverse drug reactions in clinical trials of patients with locally advanced basal cell carcinoma (laBCC) and metastatic BCC (mBCC). Treatment interruptions have been recommende
Autor:
Ivor Caro, Cloris Xue, Sergio J Azevedo, Louise Roberts, Andreia Cristina de Melo, Alberto Julius Alves Wainstein
Publikováno v:
Pigment Cell & Melanoma Research. 34:973-977
Anti-programmed death-1 agents are an established option for advanced melanoma, but the anti-programmed death-ligand 1 (anti-PD-L1) antibody atezolizumab, an agent approved for the treatment of multiple solid tumors, was not previously evaluated. Thi
Autor:
Brigitte Dréno, Claus Garbe, Isabelle Rooney, Michele Maio, Grant A. McArthur, Paolo A. Ascierto, Matthew Wongchenko, Hartmut Koeppen, Caroline Robert, Zhen Shi, Jessie J. Hsu, Yibing Yan, Antoni Ribas, Jeffrey A. Sosman, James Larkin, Paul B. Chapman, Ivor Caro, Ilsung Chang
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research, vol 25, iss 11
Purpose: Previous investigations identified transcriptional signatures associated with innate resistance to anti–programmed cell death protein 1 therapy in melanoma. This analysis aimed to increase understanding of the role of baseline genetic feat
Autor:
Ilsung Chang, Luciana Burton, Paul B. Chapman, James Larkin, Elicia Penuel, Antoni Ribas, Caroline Robert, Grant A. McArthur, Jeffrey A. Sosman, Ivor Caro, Yibing Yan, William Lu, Paolo A. Ascierto, Matthew Wongchenko
Publikováno v:
JCO Precision Oncology. :1-17
Purpose We performed a retrospective exploratory analysis to evaluate the prognostic and predictive effect of two circulating biomarkers, BRAFV600 mutant circulating tumor DNA (ctDNA) and circulating hepatocyte growth factor (cHGF), in metastatic mel
Autor:
Kalpit Shah, Caroline Robert, Gabriella Liszkay, Grant A. McArthur, Christian Hertig, Yibing Yan, Jacek Mackiewicz, Ralf Gutzmer, Judit Oláh, Paola Queirolo, Edward McKenna, Ivor Caro, Paolo A. Ascierto, Luis de la Cruz-Merino, Rodrigo Ramella Munhoz, Haocheng Li, Karl D. Lewis, Harper Forbes
Publikováno v:
Journal of Clinical Oncology. 39:9523-9523
9523 Background: The phase 3 IMspire150 study showed that first-line A+V+C improved investigator-assessed PFS vs placebo (P)+V+C in BRAFV600E/K mutation–positive advanced melanoma (hazard ratio 0.78; P=.0249). Prior biomarker analyses showed that I
Autor:
Jeffrey A. Sosman, Yibing Yan, Mark M. Kockx, Matthew Wongchenko, Priti S. Hegde, James Larkin, Isabelle Rooney, Antoni Ribas, Stephen D. Hurst, Ivor Caro, Luc Andries, Grant A. McArthur, Lukas C. Amler, Brigitte Dréno, Huibin Yue, Paolo A. Ascierto, Luciana Molinero, Ilsung Chang
Publikováno v:
Clinical Cancer Research. 23:5238-5245
Purpose: The association of tumor gene expression profiles with progression-free survival (PFS) outcomes in patients with BRAFV600-mutated melanoma treated with vemurafenib or cobimetinib combined with vemurafenib was evaluated. Experimental Design:
Autor:
C. Robert, Grant A. McArthur, Ivor Caro, A. Ribas, Shelley Coleman, R. Dummer, Matthew Wongchenko, J.M.G. Larkin, I. Chang, Alessandro Testori, Omid Hamid, Paolo A. Ascierto, David W. Hogg, J. A. Sosman, Axel Hauschild, Y Yan, Paul Lorigan, J.B.A.G. Haanen, Paul B. Chapman, Keith T. Flaherty
Publikováno v:
Melanoma Research. 26:e1-e122
Autor:
Georgina V. Long, M Gonzalez Cao, Shahneen Sandhu, A. Soria Rivas, Ivor Caro, Victoria Atkinson, Y. Song, L. Roberts, Theresa Medina, Yibing Yan
Publikováno v:
Annals of Oncology. 30:v554
Background Treatment options for patients (pts) with BRAFV600 wild type advanced melanoma following failure on anti–programmed death receptor 1 (aPD-1) therapy are limited. Melanoma is strongly driven by MAPK signaling. The MEK inhibitor cobimetini
Autor:
James Larkin, Grant A. McArthur, Jeffrey A. Sosman, C. Robert, Paul B. Chapman, A. Testori, Ivor Caro, Reinhard Dummer, Ilsung Chang, J.B.A.G. Haanen, Paul Lorigan, P.A. Ascierto, Omid Hamid, Antoni Ribas, Shelley Coleman, Keith T. Flaherty, David Hogg, Axel Hauschild
Publikováno v:
Annals of Oncology, vol 28, iss 10
Annals of Oncology
Chapman, P B, Robert, C, Larkin, J, Haanen, J B, Ribas, A, Hogg, D, Hamid, O, Ascierto, P A, Testori, A, Lorigan, P, Dummer, R, Sosman, J A, Flaherty, K T, Chang, I, Coleman, S, Caro, I, Hauschild, A & McArthur, G A 2017, ' Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study. ', Annals of Oncology, vol. 28, no. 10, pp. 2581-2587 . https://doi.org/10.1093/annonc/mdx339
Annals of Oncology
Chapman, P B, Robert, C, Larkin, J, Haanen, J B, Ribas, A, Hogg, D, Hamid, O, Ascierto, P A, Testori, A, Lorigan, P, Dummer, R, Sosman, J A, Flaherty, K T, Chang, I, Coleman, S, Caro, I, Hauschild, A & McArthur, G A 2017, ' Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study. ', Annals of Oncology, vol. 28, no. 10, pp. 2581-2587 . https://doi.org/10.1093/annonc/mdx339
Background The BRIM-3 trial showed improved progression-free survival (PFS) and overall survival (OS) for vemurafenib compared with dacarbazine in treatment-naive patients with BRAFV600 mutation–positive metastatic melanoma. We present final OS dat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::054c4ffb49194af30f36173c59c74421
https://escholarship.org/uc/item/4b31r58r
https://escholarship.org/uc/item/4b31r58r
Autor:
Eric Morinello, Jinze Li, Angela Hendricks, Ivor Caro, Stephen E. Gould, Noel Dybdal, Denzil Frost, Lisa Wong, Melissa Schutten, Donna Dambach, Thomas Larsen
Publikováno v:
Regulatory toxicology and pharmacology : RTP. 92
Vismodegib (also known as GDC-0449) is a novel small molecule inhibitor of the Hedgehog (Hh) signaling pathway currently approved for the treatment of metastatic or locally advanced basal cell carcinoma (BCC) in humans. Its tumorigenic potential was